FGFR2 (N549H)

FGFR2 · Variant type: point · HGVS: p.N549H

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Futibatinib	99.8%	0.2%	98.48
2	Nintedanib	98.9%	1.1%	90.23
3	Ponatinib	98.7%	1.3%	78.23
4	Selpercatinib	98.7%	1.4%	96.72
5	Vandetanib	98.6%	1.4%	95.74
6	Brigatinib	98.5%	1.5%	82.96
7	Alpelisib	98.3%	1.7%	97.22
8	Pemigatinib	97.6%	2.4%	98.23
9	Infigratinib	97.5%	2.5%	98.24
10	Axitinib	97.1%	2.9%	93.23
11	Lenvatinib	95.4%	4.6%	97.74
12	Pralsetinib	95.2%	4.8%	93.43
13	Erdafitinib	94.9%	5.1%	95.71
14	Pazopanib	94.2%	5.8%	97.49
15	Bosutinib	92.9%	7.1%	87.22
16	Dacomitinib	92.2%	7.8%	97.99
17	Canertinib	91.6%	8.4%	96.49
18	Erlotinib	91.1%	8.9%	99.75
19	Dasatinib	90.9%	9.1%	87.97
20	Sunitinib	90.2%	9.8%	91.73
21	Repotrectinib	88.7%	11.3%	84.21
22	Tivozanib	84.8%	15.2%	92.42
23	Entrectinib	84.3%	15.7%	93.69
24	Fedratinib	84.2%	15.8%	96.21
25	Alectinib	79.6%	20.4%	95.49

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Futibatinib	99.8%	99.3%	+0.5%
Nintedanib	98.9%	97.0%	+2.0%
Ponatinib	98.7%	99.4%	-0.7%
Selpercatinib	98.7%	95.0%	+3.6%
Vandetanib	98.6%	90.8%	+7.8%
Brigatinib	98.5%	96.1%	+2.5%
Alpelisib	98.3%	98.9%	-0.6%
Pemigatinib	97.6%	98.7%	-1.1%
Infigratinib	97.5%	98.8%	-1.3%
Axitinib	97.1%	96.1%	+1.0%
Lenvatinib	95.4%	85.4%	+10.0%
Pralsetinib	95.2%	93.2%	+1.9%
Erdafitinib	94.9%	99.0%	-4.1%
Pazopanib	94.2%	88.9%	+5.3%
Bosutinib	92.9%	—	—
Dacomitinib	92.2%	—	—
Canertinib	91.6%	—	—
Erlotinib	91.1%	—	—
Dasatinib	90.9%	—	—
Sunitinib	90.2%	—	—
Repotrectinib	88.7%	79.8%	+8.9%
Tivozanib	84.8%	—	—
Entrectinib	84.3%	81.5%	+2.7%
Fedratinib	84.2%	—	—
Alectinib	79.6%	—	—

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 16.2ms